Intelligence Unit
Special Reports
Special Events
Subscribe
Sponsored
Departments
- Leadership
- Finance
- Technology
- Physicians
- Community Hospitals
- Health Plans
- Marketing
- Quality
- Nursing
- HR
Follow Us
Lower sales of Tysabri predicted
Boston Globe, August 6, 2008
It is expected that fewer patients will be taking Tysabri, used to treat multiple sclerosis, as two more patients have been diagnosed with a potentially fatal brain disease. Financial analysts predict that the drug will have only about 75,000 users by 2013, which is below Biogen Idec Inc.'s goal of 100,000.
Most Viewed
Most Emailed
- $6.4B Henry Ford, Beaumont Merger Failed on Cultural Hurdles
- Don't Let Nurses Sink Your Bottom Line
- Hospitals Profit On Bloodstream Infections
- Fortunately, Angelina Jolie Isn't On Medicare
- Less Blood Testing for Some Surgeries Safe, Cost Effective
- How Chargemaster Data May Affect Hospital Revenue
- Primary Care Docs Average More Hospital Revenue Than Specialists
- Lower ED Margins Demand a Better Strategy
- House Lawmakers Grill CMS Over Health Exchange Navigators
- ED Physicians Key to Half of Hospital Admissions
